News | April 23, 2024
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
Open a printable version of this pageEmail the URL of this page to a friend
Open a printable version of this pageEmail the URL of this page to a friend
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Subscribe To Our Newsletter & Stay Updated
